Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Change in Accured Expenses: 2020-2025

Historic Change in Accured Expenses for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $1.2 million.

  • Insight Molecular Diagnostics' Change in Accured Expenses rose 81.36% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$205,000, marking a year-over-year increase of 31.89%. This contributed to the annual value of $967,000 for FY2024, which is 120.33% up from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Change in Accured Expenses stood at $1.2 million for Q3 2025, which was up 137.81% from -$3.1 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year Change in Accured Expenses high stood at $1.2 million for Q3 2025, and its period low was -$3.1 million during Q2 2025.
  • Over the past 3 years, Insight Molecular Diagnostics' median Change in Accured Expenses value was $126,000 (recorded in 2023), while the average stood at -$427,182.
  • Per our database at Business Quant, Insight Molecular Diagnostics' Change in Accured Expenses crashed by 12,576.19% in 2023 and then skyrocketed by 415.08% in 2024.
  • Over the past 5 years, Insight Molecular Diagnostics' Change in Accured Expenses (Quarterly) stood at $244,000 in 2021, then slumped by 151.23% to -$125,000 in 2022, then plummeted by 351.20% to -$564,000 in 2023, then spiked by 224.82% to $704,000 in 2024, then spiked by 81.36% to $1.2 million in 2025.
  • Its Change in Accured Expenses stands at $1.2 million for Q3 2025, versus -$3.1 million for Q2 2025 and $1.0 million for Q1 2025.